The Aristocrat Nobody Wanted: Why (MDT) Is Worth a Second Look Right Now

(MDT) has raised its dividend for 48 consecutive years, yet trades at just 14x forward earnings. On a trailing basis it is 24x vs. (ISRG) at 57x and (SYK) at 40x.

The 5-year dividend CAGR is 4.4%, slowing to 2.0% over three years. This is a yield anchor at 3.3%, not a fast compounder. Payout ratio of 50.2% keeps the streak sustainable.

FCF yield sits near 4.87% with $5.41B in trailing free cash flow. Ten straight years of positive FCF. The income is backed by real cash generation.

Revenue grew 8.7% in the most recent quarter, the company's strongest enterprise growth in 10 quarters. Full-year guidance raised then reiterated. Two consecutive beats matter.

Blended fair value from multiple sources lands near $107-$108 vs. current price near $86, implying roughly 24-25% upside before the 3.3% yield. GNG Research internal FV is $94.01.

EPS beat rate over the last 8 quarters: 100%. The market is pricing this like a business that disappoints. The data from the GNG Research terminal shows otherwise.

There is a particular kind of unloved stock that the market prices like it forgot how to grow, while the actual business keeps quietly putting up decent numbers. Medtronic sits squarely in that bucket right now. The stock has spent two years drifting lower, trailing its medtech peers, absorbing skepticism from every direction. Meanwhile, the company just reported its strongest quarterly revenue growth in ten quarters, raised full-year guidance, and reiterated it after doing so. That gap between the price action and the operating reality is where the investment case lives.

I do not own (MDT) today. This piece is about whether it earns a spot in a portfolio built around income quality and value discipline. My read is that it does, with some important caveats about what you are actually buying.

The Aristocrat Nobody Wanted: Why (MDT) Is Worth a Second Look Right Now

Keep Reading